Alvea

What Alvea does

Alvea was a private biotechnology company that operated from January 2022 until October 2023, founded by Grigory Khimulya (CEO), Cate Hall (COO), Kyle Fish (CTO), and Maximilian Schons (CMO) to build accelerated drug development capabilities aimed at pandemic preparedness. The company's core product was Alveavax, a room temperature-stable plasmid DNA vaccine candidate optimized for the SARS-CoV-2 Omicron variant, which the company advanced from conception (December 2021) to first-in-human dosing (June 2022) in 196 days, a timeline the company claimed was faster than any other startup on record in the prior 35 years based on its review of clinicaltrials.gov and Crunchbase data. The company also developed an underlying accelerated drug development platform designed to in-house, automate, and re-engineer rate-limiting workflows in drug design, discovery, and clinical development, aligned with the CEPI 100-day pandemic response goal.

Alvea targeted low and middle income countries with limited access to existing vaccines as its primary customer segment for DNA vaccine distribution, and explored a partnerships program to make its rapid development platform available to other biotechs through licensing-style arrangements. The company was funded by Open Philanthropy, MetaPlanet, and Good Forever, an investor base aligned with biosecurity, pandemic preparedness, and effective altruism capital pools. Alvea never generated commercial revenue; it did not disclose pricing, did not commercialize any product, and did not execute its partnerships program before winding down.

In 2023, after discontinuing its lead candidate Alveavax-v1.2 during the Phase 1 follow-up period as the case for large-scale impact weakened against the evolving pandemic landscape, Alvea wound down operations, returned remaining funds to investors, and helped establish Panoplia Laboratories, a nonprofit focused on early-stage R&D for impact-focused medical countermeasures, to continue development of the vaccine technologies.

Name

Alvea

Legal name

Alvea LLC

Website

https://alvea.bio

Company type

Private

Founded year

2022

Operating status

Closed

Headcount range

11–50 employees

Short description

Alvea was a private biotechnology company (2022–2023) that built an accelerated DNA vaccine development platform, achieving a 196-day founding-to-Phase-1 record with its Omicron COVID-19 vaccine before winding down operations in October 2023.

Ownership category

akta.pro rank

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAEAF

Pandemic Preparedness & Rapid-Response Vaccines

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAAAEAC

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAJAOAF

Immunization & Vaccine Access Partnerships (Global Vaccine Alliances)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAAAKAE

Plasmid DNA & mRNA Manufacturing Services

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

Keywords

• DNA vaccine development
• Pandemic preparedness
• Accelerated drug development
• Biotechnology platform
• Infectious disease countermeasures

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Vaccine Development Services: Alvea explored making its rapid development platform available to other biotechs through a partnerships program. The company initially developed its own vaccine candidate before exploring service-based applications of its accelerated drug development capabilities.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Alvea was a biotechnology company that internally developed pandemic medical countermeasures, most notably Alveavax, a shelf-stable plasmid DNA COVID-19 vaccine that reached Phase 1 clinical trials. Beyond any single product, the company built an accelerated drug development platform designed to in-house, automate, and re-engineer the rate-limiting workflows of clinical development in order to take new medicines from molecule to clinical trials far faster than the industry standard.

Product overview

Alvea was a technology company building an engine for warp speed drug development, dedicated to dramatically reducing the time from molecule to trials for new medicines. The company's primary product was Alveavax, a plasmid DNA Omicron variant-optimized COVID-19 booster vaccine that set the record for fastest startup to take a new drug from founding to Phase 1 clinical trial (196 days). Alvea also operated an accelerated drug development platform designed to in-house, automate, and re-engineer rate-limiting workflows in drug design, discovery, and clinical development. The company has since wound down operations as of October 2023.

Differentiator

Problem solved

Functional benefit

Brands

• Alveavax: Plasmid DNA Omicron variant-optimized COVID-19 booster vaccine; later referred to as Alveavax-v1.2

Quantifiable outcome

• 196 days from startup formation to first patient dosing - fastest on record for any startup taking a new drug into Phase 1 clinical trial in the last 35 years

Named customers2 records

Segments1 record

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Panoplia LaboratoriesminorStrategic or Co-development Partner · 12 October 2023New nonprofit created as part of Alvea's wind down process, focused on early-stage R&D for impact-focused medical countermeasures. Alvea is working to transfer vaccine technologies developed at Alvea to Panoplia for continued development.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• CureVac: CureVac is an mRNA technology company focused on developing vaccines for infectious diseases, including pandemic preparedness. Operates in the same rapid-response vaccine development space as Alvea.
• Inovio Pharmaceuticals: Inovio is a DNA vaccine and DNA medicine developer with a CELLECTRA electroporation delivery platform. Directly comparable to Alvea's plasmid DNA vaccine approach targeting infectious diseases including COVID-19 variants.
• Zydus Cadila: Zydus developed ZyCoV-D, the world's first approved plasmid DNA COVID-19 vaccine, validating the DNA vaccine modality. Directly comparable as a plasmid DNA vaccine developer targeting infectious disease.

Broad incumbents

• Pfizer: Pfizer is a global pharmaceutical incumbent with a leading COVID-19 vaccine (Comirnaty with BioNTech). Comparable as a dominant vaccine distributor and pandemic countermeasure developer at scale.
• BioNTech: BioNTech is a leading mRNA-based vaccine developer (notably the Pfizer-BioNTech COVID-19 vaccine) with platform-level capabilities in rapid vaccine design. It competes with DNA vaccine approaches on pandemic response timelines.
• Takeda Pharmaceutical (Vaccines): Takeda has a global vaccines business including pandemic preparedness partnerships (e.g., with BARDA for COVID-19 manufacturing). Comparable as a major vaccine player distributing to LMIC markets that Alvea also targeted.
• Moderna: Moderna is the leading mRNA vaccine company with pandemic preparedness partnerships (including with CEPI). It represents the broader mRNA incumbent that Alvea's DNA approach was designed to complement or compete with in speed-to-clinic.
• Sanofi Pasteur: Sanofi Pasteur is the vaccines division of Sanofi, a global leader in vaccine development including pandemic preparedness partnerships (e.g., BARDA-funded manufacturing). It represents an established player in the same target space with broader portfolio reach.

Emerging players

• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company with COVID-19 vaccine and self-amplifying RNA platform technology. Comparable to Alvea as a smaller vaccine platform player targeting infectious diseases.

Others

• CEPI (Coalition for Epidemic Preparedness Innovations): CEPI is the global partnership that funds and coordinates vaccine development for epidemic threats and set the '100-day' pandemic preparedness goal referenced by Alvea. Comparable as an enabling ecosystem participant and likely funding partner.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/alveabio
• LinkedInlinkedin.com/company/alvea

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvea